Lynn M. Schuchter, MD, from the University of Pennsylvania, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.
Lynn M. Schuchter, MD
Advertisement
Articles by Lynn M. Schuchter, MD
Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.
Dr. Lynn M. Schuchter from Penn Medicine on the Progression of Melanoma Care over the past 25 years
Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program
Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research
Dr. Lynn Schuchter chief of Hematology Oncology at Penn Medicine Reserves BRAF Testing for Advanced Melanoma
Dr. Schuchter chief of Hematology Oncology at Penn Medicine on Testing for a BRAF Mutation in Melanoma
Advertisement
Latest Updated Articles
Dr. Schuchter Discusses the Treatment of MelanomaJuly 3rd 2013
Dr. Schuchter Discusses Nivolumab in MelanomaAugust 21st 2013
Dr. Schuchter on Testing for a BRAF Mutation in MelanomaJune 27th 2011
Dr. Schuchter Limits BRAF Testing to Advanced MelanomaJune 30th 2011
Dr. Schuchter on the Next Steps in Melanoma ResearchJuly 7th 2011
Dr. Schuchter on Managing Ipilimumab's Side EffectsJuly 13th 2011
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5